1.COP-BLAM III(cyclophosphamide/vincristine/prednisolone/bleomycin/ adriamycin/procarbazine) combination chemotherapy for the treatment of intermediate and high grade non-Hodgkin's lymphoma.
Keong Hae JUNG ; Young Iee PARK ; Kee Heung LEE ; Young Suk PARK ; Chang In SUH ; Won Ki KANG ; Heung Tae KIM ; Cheol Won SUH ; Dae Seog HEO ; Yung Jue BANG ; Seonyang PARK ; Noe Kyeong KIM
Journal of the Korean Cancer Association 1992;24(4):586-595
No abstract available.
Drug Therapy, Combination*
;
Lymphoma, Non-Hodgkin*
2.Treatment of intermediate-grade non-Hodgkin's lymphoma with CAMP-MOB combination chemotherapy.
Chang In SUH ; Heung Tae KIM ; Dong Bok SHIN ; Jae Hoon LEE ; Dae Seog HEO ; Yung Jue BANG ; Seonyang PARK ; Byoung Kook KIM ; Noe Kyeong KIM
Journal of the Korean Cancer Association 1992;24(1):102-108
No abstract available.
Drug Therapy, Combination*
;
Lymphoma, Non-Hodgkin*
3.Modified COP-BLAM combination chemotherapy for the non-Hodgkin's lymphoma.
Journal of the Korean Cancer Association 1991;23(2):331-336
No abstract available.
Drug Therapy, Combination*
;
Lymphoma, Non-Hodgkin*
4.Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma.
Hyungwoo CHO ; Dok Hyun YOON ; Jwa Hoon KIM ; Young Bo KO ; Byoung Soo KWON ; In Hye SONG ; Cheolwon SUH
The Korean Journal of Internal Medicine 2016;31(3):605-607
No abstract available.
Drug Therapy*
;
Lymphoma, Non-Hodgkin*
;
Sarcoidosis*
5.Hepatic candidiasis developed after high dose chemotherapy for non-hodgkin's lymphoma.
Yong Hwan SONG ; Yoon Koo KANG
Korean Journal of Medicine 1999;57(5):961-961
No abstract available.
Candidiasis*
;
Drug Therapy*
;
Lymphoma, Non-Hodgkin*
6.Hepatic candidiasis developed after high dose chemotherapy for non-hodgkin's lymphoma.
Yong Hwan SONG ; Yoon Koo KANG
Korean Journal of Medicine 1999;57(5):961-961
No abstract available.
Candidiasis*
;
Drug Therapy*
;
Lymphoma, Non-Hodgkin*
7.ProMACE/MOPP combination chemotherapy in advanced, intermediate and high grade non-Hodgkin's lymphoma.
Hong Su KIM ; Chang Hyun CHOI ; Jun Gu KWACK ; Jong Ho WON ; Dae Sik HONG ; Hee Sook PARK
Korean Journal of Hematology 1991;26(1):23-30
No abstract available.
Drug Therapy, Combination*
;
Lymphoma, Non-Hodgkin*
8.MACOP-B and COPBLAM-1 combination chemotherapy for the treatment of non-Hodgkin's lymphoma.
Yong Tae KIM ; Dong Jo KIM ; Eun Kyung CHO ; Chong Soon HAN ; Jong Yul JIN ; Chong Won PARK ; Dong Jip KIM
Korean Journal of Hematology 1992;27(2):283-291
No abstract available.
Drug Therapy, Combination*
;
Lymphoma, Non-Hodgkin*
9.COP-BLAM V(cyclophosphamide/vincristine/prednisolone/bleomycin/ adriamycin/procarbazine) combination chemotherapy for the treatment of intermediate and high grade non-Hodgkin's lymphoma.
Young Iee PARK ; Kee Heung LEE ; Keong Hae JUNG ; Sung Soo YOON ; Yeong Huck IM ; Jung Soon JANG ; Jae Yong LEE ; Dae Suck HEO ; Yung Jue BANG ; Seonyang PARK ; Byoung Kook KIM ; Noe Kyeong KIM
Journal of the Korean Cancer Association 1992;24(2):268-276
No abstract available.
Drug Therapy, Combination*
;
Lymphoma, Non-Hodgkin*
10.Clinical practice guideline for lympoma in China (2021 Edition).
Chinese Journal of Oncology 2021;43(7):707-735
Lymphoma is one of the most common malignancies in China. In China, there were 6 829 new Hodgkin lymphoma cases and 2 807 deaths in 2020, with 92 834 new non-Hodgkin lymphoma cases and 54 351 deaths. Due to the complicated pathological subtypes and heterogeity, the treatment strategies for lymphoma vary largely. In recent years, with the deep understanding for the nature of lymphoma, much research progress has been achieved in the diagnosis and treatment, leading to a remarkable improvement in survival outcome of patients. In order to update the progress in the treatment of lymphoma worldwide timely, and further improve the level of standardized diagnosis and treatment of lymphoma in China, the China Anti-cancer Association Lymphoma Committee, Chinese Association for Clinical Oncologists, and Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare organized experts to formulate "Clinical practice guideline for lympoma in China (2021 Edition)" .
China/epidemiology*
;
Hodgkin Disease/drug therapy*
;
Humans
;
Lymphoma/therapy*
;
Lymphoma, Non-Hodgkin/drug therapy*
;
Medical Oncology